USPTO serial 97409708
ECLIPSYS
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Oct 3, 2023
- Examiner
- BRACEY, KAREN
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with ECLIPSYS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Rob LeBlanc
Rob LeBlanc Greenberg Traurig, LLP2200 Ross Avenue, Suite 5200Dallas, TX 75201United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemicals for use in science; chemical compositions and agents for use in science; chemical preparations for use in the manufacture of pharmaceutical drugs; biological preparations for use in science; chemicals for biotechnological manufacturing processes; diagnostic preparations used for scientific or research use; reagents used for scientific or research use; proteins in raw material form for scientific or research use; none of the aforesaid relating to reagents and chemicals for use in relation to biochemicals, oligonucleotides, oligonucleotide conjugates, DNA primers, DNA, genetic, and oligonucleotide probes, and quenchers | ACTIVE | — |
| 005 | Pharmaceuticals, medicinal and veterinary preparations for the diagnosis and treatment of damaged tissue, dermatological diseases and disorders, infectious diseases, pain, obesity, cognitive disorders, inflammation, viral diseases and disorders, neurological diseases and disorders, endocrine diseases and disorders, metabolic diseases and disorders, genitourinary diseases and disorders, musculoskeletal diseases and disorders, cardiovascular diseases and disorders, cardiopulmonary diseases and disorders, oncological diseases and disorders, respiratory diseases and disorders, hepatological diseases and disorders, gastrointestinal diseases and disorders, psychiatric diseases and disorders and immune system diseases and disorders; diagnostic preparations for medical and veterinary use; medicines and biotechnological preparations for medical use for the diagnosis and treatment of damaged tissue, dermatological diseases and disorders, infectious diseases, pain, obesity, cognitive disorders, inflammation, viral diseases and disorders, neurological diseases and disorders, endocrine diseases and disorders, metabolic diseases and disorders, genitourinary diseases and disorders, musculoskeletal diseases and disorders, cardiovascular diseases and disorders, cardiopulmonary diseases and disorders, oncological diseases and disorders, respiratory diseases and disorders, hepatological diseases and disorders, gastrointestinal diseases and disorders, psychiatric diseases and disorders and immune system diseases and disorders; biological and chemical reagents for medical use; pharmaceutical drugs for medical purposes for the diagnosis and treatment of damaged tissue, dermatological diseases and disorders, infectious diseases, pain, obesity, cognitive disorders, inflammation, viral diseases and disorders, neurological diseases and disorders, endocrine diseases and disorders, metabolic diseases and disorders, genitourinary diseases and disorders, musculoskeletal diseases and disorders, cardiovascular diseases and disorders, cardiopulmonary diseases and disorders, oncological diseases and disorders, respiratory diseases and disorders, hepatological diseases and disorders, gastrointestinal diseases and disorders, psychiatric diseases and disorders and immune system diseases and disorders; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; none of the aforesaid goods being for the treatment and care of wounds and none of the aforesaid relating to reagents and chemicals for use in relation to biochemicals, oligonucleotides, oligonucleotide conjugates, DNA primers, DNA, genetic, and oligonucleotide probes, and quenchers | ACTIVE | — |
| 042 | Scientific and technological services, namely, scientific analysis, testing, engineering, development, research, and design in the field of drug discovery and the identification and development of pharmaceutical and medicinal preparations; consultancy relating to product research and development in the field of pharmaceutical and medicinal preparations for therapeutic use; research and development in the field of medical diagnostics; biotechnological and chemical testing; research and development in the pharmaceutical, chemical and biotechnological fields; research and development in the field of medicinal preparations; drug discovery services; development of pharmaceutical preparations and medicines; pharmaceutical drug development services; none of the aforesaid relating to reagents and chemicals for use in relation to biochemicals, oligonucleotides, oligonucleotide conjugates, DNA primers, DNA, genetic, and oligonucleotide probes, and quenchers | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Amphista Therapeutics Limited
- Other trademarks owned by Amphista Therapeutics Limited
- Other trademarks owned by Amphista Therapeutics Limited
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named ECLIPSYS
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Apr 22, 2025 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Apr 22, 2025 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 22, 2025 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Apr 22, 2025 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Apr 22, 2025 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Oct 3, 2023 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Oct 3, 2023 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jul 18, 2023 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jul 18, 2023 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jun 28, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jun 12, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jun 1, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 31, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 31, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 3, 2023 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 3, 2023 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 3, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 2, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 15, 2023 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Feb 15, 2023 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Feb 15, 2023 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Feb 14, 2023 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Feb 14, 2023 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Feb 14, 2023 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Feb 14, 2023 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 14, 2023 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Feb 14, 2023 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Jun 2, 2022 | TAEA | TEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED | — |
| Jun 2, 2022 | PARI | TEAS VOLUNTARY AMENDMENT RECEIVED | — |
| May 18, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| May 17, 2022 | NWAP | NEW APPLICATION ENTERED | — |